Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
A phase 2/3 trial testing PF-08634404 in non-small-cell lung cancer, now recruiting.
Overview
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07226999, led by Pfizer, and recruiting when checked on 2026-09-11. Official title: A global phase 2/3 interventional study of PF-08634404 in combination with chemotherapy in participants with extensive stage small cell lung cancer. Planned enrolment is 550 participants (estimated). The study started in 2025-12-09 and primary completion is expected in 2030-06-14. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares PF-08634404, Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shares PF-08634404, Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Shares PF-08634404, Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares PF-08634404, Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.